Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo.

Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo.

Item
http://www.wikidata.org/entity/Q37733073
Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer.3,3'-Diindolylmethane: A Promising Sensitizer of γ-IrradiationTargeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block SignalingMitotic catastrophe is a putative mechanism underlying the weak correlation between sensitivity to carbon ions and cisplatin.Cell cycle proteins as promising targets in cancer therapyConvallaria keiskei as a novel therapeutic alternative for salivary gland cancer treatment by targeting myeloid cell leukemia-1.ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade.
P2860

Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo.

Item
http://www.wikidata.org/entity/Q37733073
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rigosertib is a more effective ...... rcinoma, in vitro and in vivo.
@en
Rigosertib is a more effective ...... rcinoma, in vitro and in vivo.
@nl
type
label
Rigosertib is a more effective ...... rcinoma, in vitro and in vivo.
@en
Rigosertib is a more effective ...... rcinoma, in vitro and in vivo.
@nl
prefLabel
Rigosertib is a more effective ...... rcinoma, in vitro and in vivo.
@en
Rigosertib is a more effective ...... rcinoma, in vitro and in vivo.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Rigosertib is a more effective ...... rcinoma, in vitro and in vivo.
@en
P2093
P2860
P304
P31
P356
10.1016/J.IJROBP.2013.12.051
P407
P433
P478
P50
P577
P5875
P698
P921
P932